FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315615422> ?p ?o ?g. }

• W2315615422 endingPage "279" @default.
• W2315615422 startingPage "279.1" @default.
• W2315615422 abstract "<h3>Background</h3> The overall response rate (defined as low disease activity [LDA] related to DAS28[CRP]) to abatacept associated with MTX was 57.1% at 6 months in the 6-month open-label abatacept Power Doppler Ultrasonography (PDUS; APPRAISE) study in patients with RA and inadequate response to MTX [1–4]. <h3>Objectives</h3> The objective of this exploratory analysis was to identify potential predictors of response to the abatacept–MTX combination by whole blood gene expression profiling in order to optimize treatment choice. <h3>Methods</h3> 104 patients with active RA and inadequate response to MTX were treated with abatacept + MTX at the approved doses. Whole blood in Paxgene tubes was collected for each RA patient at baseline. At 6 months, RA patients were categorized as responders if DAS28 was ≤3.2 (LDA) and non-responders if DAS28 was >3.2. Baseline RNAs from a first set of RA patients (n=44) were hybridized to a whole human genome 4 x 44K microarray Agilent slide to identify a gene combination able to separate responders and non-responders with the GeneSpring GX software. A <i>t</i>-test with false discovery rate correction for multiple testing (p<0.05) was used to determine mRNAs differentially regulated between responders and non-responders. This gene combination was validated with a second set of RA patients (n=32) by qRT-PCR. <h3>Results</h3> Among these 104 RA patients, 28 were excluded from the following analysis because of missing clinical data (n=13), poor integrity of whole blood mRNA (RIN<7) (n=6), low concentration rate for reverse transcription (n=7), qRT-PCR failures (n=2). Responders (n=45) and non-responders (n=31) had similar baseline characteristics [1]. In a first set of 44 enrolled RA patients (25 responders and 19 non-responders), 87 mRNAs identified by microarray analysis were expressed as a function of the response to treatment and an unsupervised hierarchical clustering almost perfectly separated these responders from non-responders. The informativeness of 12 of these 87 transcripts (selected with the lowest p-value), as measured by qRT-PCR, was re-assessed in a second set of 32 RA patients (20 responders and 12 non-responders). The combined levels of these 12 transcripts properly classified 23 out of 32 patients with a sensitivity of 80%, a specificity of 66.7%, a positive predictive value of 80%, and a negative predictive value of 66.8%. This combination enriched with more genes is in progress in order to better classify the second set of RA patients. <h3>Conclusions</h3> Our gene profiling results obtained by a non-invasive procedure have generated a list of 12 candidate genes that were associated with a response to abatacept combined with MTX in this study. This combination of genes needs to be further validated in other RA studies to support their utility as a potential diagnostic assay for predicting abatacept response in an effort to personalize treatment for RA. <h3>References</h3> D9Agostino MA et al. Ann Rheum Dis 2012;71(Suppl 3):86. D9Agostino MA, et al. Arthritis Rheum 2012;64(Suppl):S352. D9Agostino MA, et al. Arthritis Rheum 2012;64(Suppl):S353. Lequerre T, et al Arthritis Rheum 2013;65(Suppl):S811. <h3>Disclosure of Interest</h3> : T. Lequerré Grant/research support: BMS, Consultant for: BMS, C. Derambure: None declared, M. D9Agostino: None declared, M. Hiron: None declared, P. Gaudin Consultant for: BMS, C. Gaillez Shareholder of: BMS, Employee of: BMS, M. Le Bars Shareholder of: BMS, Employee of: BMS, O. Vittecoq Consultant for: BMS Advisory Board <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1567" @default.
• W2315615422 created "2016-06-24" @default.
• W2315615422 creator A5002428943 @default.
• W2315615422 creator A5003660554 @default.
• W2315615422 creator A5009452487 @default.
• W2315615422 creator A5037284597 @default.
• W2315615422 creator A5060019340 @default.
• W2315615422 creator A5061804201 @default.
• W2315615422 creator A5063024591 @default.
• W2315615422 creator A5083216357 @default.
• W2315615422 date "2014-06-01" @default.
• W2315615422 modified "2023-10-15" @default.
• W2315615422 title "THU0277 Gene Expression in Whole Blood Predicts the Abatacept–Methotrexate Combination Responsiveness in Rheumatoid Arthritis: Preliminary Results from the Power Doppler Ultrasonography Appraise Study" @default.
• W2315615422 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1567" @default.
• W2315615422 hasPublicationYear "2014" @default.
• W2315615422 type Work @default.
• W2315615422 sameAs 2315615422 @default.
• W2315615422 citedByCount "0" @default.
• W2315615422 crossrefType "journal-article" @default.
• W2315615422 hasAuthorship W2315615422A5002428943 @default.
• W2315615422 hasAuthorship W2315615422A5003660554 @default.
• W2315615422 hasAuthorship W2315615422A5009452487 @default.
• W2315615422 hasAuthorship W2315615422A5037284597 @default.
• W2315615422 hasAuthorship W2315615422A5060019340 @default.
• W2315615422 hasAuthorship W2315615422A5061804201 @default.
• W2315615422 hasAuthorship W2315615422A5063024591 @default.
• W2315615422 hasAuthorship W2315615422A5083216357 @default.
• W2315615422 hasConcept C126322002 @default.
• W2315615422 hasConcept C143998085 @default.
• W2315615422 hasConcept C203014093 @default.
• W2315615422 hasConcept C2777575956 @default.
• W2315615422 hasConcept C2779338263 @default.
• W2315615422 hasConcept C2779605438 @default.
• W2315615422 hasConcept C2780653079 @default.
• W2315615422 hasConcept C2781059491 @default.
• W2315615422 hasConcept C71924100 @default.
• W2315615422 hasConceptScore W2315615422C126322002 @default.
• W2315615422 hasConceptScore W2315615422C143998085 @default.
• W2315615422 hasConceptScore W2315615422C203014093 @default.
• W2315615422 hasConceptScore W2315615422C2777575956 @default.
• W2315615422 hasConceptScore W2315615422C2779338263 @default.
• W2315615422 hasConceptScore W2315615422C2779605438 @default.
• W2315615422 hasConceptScore W2315615422C2780653079 @default.
• W2315615422 hasConceptScore W2315615422C2781059491 @default.
• W2315615422 hasConceptScore W2315615422C71924100 @default.
• W2315615422 hasIssue "Suppl 2" @default.
• W2315615422 hasLocation W23156154221 @default.
• W2315615422 hasOpenAccess W2315615422 @default.
• W2315615422 hasPrimaryLocation W23156154221 @default.
• W2315615422 hasRelatedWork W2014382789 @default.
• W2315615422 hasRelatedWork W2039301982 @default.
• W2315615422 hasRelatedWork W2047008351 @default.
• W2315615422 hasRelatedWork W2241028821 @default.
• W2315615422 hasRelatedWork W2247417600 @default.
• W2315615422 hasRelatedWork W2914834251 @default.
• W2315615422 hasRelatedWork W2987008883 @default.
• W2315615422 hasRelatedWork W3046617813 @default.
• W2315615422 hasRelatedWork W3048731972 @default.
• W2315615422 hasRelatedWork W4256133046 @default.
• W2315615422 hasVolume "73" @default.
• W2315615422 isParatext "false" @default.
• W2315615422 isRetracted "false" @default.
• W2315615422 magId "2315615422" @default.
• W2315615422 workType "article" @default.